The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Open accessAbstract
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cardiovascular disease (CVD) remains a significant threat to people with obesity and type 2 diabetes (T2D), with a two to three times higher incidence compared to people without diabetes or obesity [1, 2].”
From Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Self-citationStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Research works printed but not linked: 2
- Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. · DOI · Paper page
- Disease C, Management R. Standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103-s123.
Cited by
Sorted by citations
Items 101–200 of 472
Kiyak‐Kirmaci, H., Hazar‐Yavuz, A. N., Polat, E. B., Alsaadoni, H., Çilingir‐Kaya, Ö. T., Aktaş, H. Ş., & Elçioğlu, H. K. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109063 · Cited by 7
Endocan is Related to Increased Cardiovascular Risk in Type 2 Diabetes Mellitus Patients
Klisic, A. N., Kotur‐Stevuljević, J., & Ninić, A. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0050 · Cited by 9
Prameswari, A. S., Kalanjati, V. P., Yuliawati, T. H., Abdurachman, & Miftahussurur, M. (2023) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2024.01.002 · Cited by 7
Rocha, S., Amaro, A., Ferreira-Junior, M. D., Proença, C., Silva, A. M. S., Costa, V. M., Oliveira, S., Fonseca, D. A., Silva, S., Corvo, M. L., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020261 · Cited by 7
“Hence, these complications pose significant concerns regarding the prognosis of DM [10,11].”
BackgroundLin, Y., Wang, Y., Zhang, Q., Gao, R., Chang, F., Li, B., Huang, K., Cheng, N., & He, X. (2024) · Biomolecules · doi:10.3390/biom14091193 · Cited by 7
“As IR worsens, pancreatic function is impaired and insulin secretion decreases [7].”
BackgroundIncreased risk of vascular complications in patients with type 2 diabetes and fatty liver disease
Sun, W., Liu, D., Yang, T., Zhou, Z., Li, D., Zhao, Z., Zhang, X., Wang, L., & Li, L. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01766-3 · Cited by 7
“In patients with T2DM and SLD, insulin resistance, production of atherogenic lipids, multiple proinflammatory, prothrom-bogenic, and vasoactive mediators might result in the development and progression of arterial stiffness, CVD and stroke [37].”
BackgroundSun, M., Lu, Z., Chen, W., Lv, S., Fu, N., Yang, Y., Wang, Y., Miao, M., Wu, S., & Zhang, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119117 · Cited by 7
Zhang, X., Wang, C., Min, R., Zhou, Q., Qi, Y., & Fan, J. (2024) · Nutrition Research · doi:10.1016/j.nutres.2024.03.002 · Cited by 7
Li, Y., Luo, J., Bao, K., Wei, Q., Wang, X., Chen, J., Zhang, T., Wang, F., & Zhu, Y. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111870 · Cited by 6
Self-citationChen, F., Wang, J., He, S., He, Y., An, Y., Gong, Q., Chen, X., Shuai, Y., Wang, X., Chen, Y., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03749-6 · Cited by 7
Lin, J., Zhang, X., Ge, W., Duan, Y., Zhang, X., Zhang, Y., Dai, X., Jiang, M., Zhang, X., Zhang, J., et al. (2025) · Diabetes · doi:10.2337/db24-0543 · Cited by 7
Li, Q. (2025) · Forests · doi:10.3390/f16020310 · Cited by 6
Xiao, Y., Zhao, Z., Chen, B., Sun, J., Wang, L., Wang, Y., Nan, Z., & Zhang, Q. (2025) · PeerJ · doi:10.7717/peerj.19221 · Cited by 7
“Therefore, it is urgent to explore more drugs for the treatment of T2DM ( Ma et al., 2022 ; Wang et al., 2022 ).”
Kuck, L., Griffith, T. A., McNamee, A. P., Peart, J. N., Wilson, J. H., Sharma, A., Sharma, L. A., Robertson, K., Toit, E. F. D., & Simmonds, M. J. (2025) · FEBS Journal · doi:10.1111/febs.70157 · Cited by 6
Jiang, N., Ma, Y., Chen, H., & Li, C. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1663094 · Cited by 6
Li, Z., Li, A., Sun, D., & Shu, Y. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2505154 · Cited by 6
“Notably, in clinical practice, cardiovascular disease is most often the primary cause of mortality in patients with diabetes mellitus (DM) [3].”
BackgroundMoiynbayeva, S., Akhmetov, V., Narymbayeva, N., Shaikova, K., Makhanbetkulova, D., Bapayeva, M., Abdirova, T., Popova, T., & Karibayeva, I. K. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1456187 · Cited by 12
Xu, X., Wu, H., & Wei, Q. (2024) · Endocrine · doi:10.1007/s12020-024-04039-0 · Cited by 6
“It has been suggested that higher BMI was signi fi cantly associated with an increased risk of atherosclerotic disease in T2DM patients, suggesting that weight management could be critical in mitigating this risk [3].”
Jiao, M., Chen, J., Wang, X., Tao, W., Feng, Y., Yang, H.-J., Yang, H., Zhao, S., Yang, Y., & Li, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01583-1 · Cited by 6
Self-citationYoon, Y., Kim, T. O., Park, G., Lee, J., Roh, J., Lee, J., Lee, K., Lee, P. H., Choe, J., Kim, Y., et al. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.03.005 · Cited by 6
Xia, Z., Song, L., Fang, D., You, W., Li, F., Zheng, D., Li, Y., Lin, L., Dou, J., Su, X., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01723-1 · Cited by 6
Self-citationYaluri, A. S., Tkáč, I., Tokarčíková, K., Kozelová, Z., Rašiová, M., Javorský, M., & Kozárová, M. (2023) · Metabolites · doi:10.3390/metabo13080887 · Cited by 6
“T2D is associated with accelerated atherosclerosis leading to 2–3 times increased incidence of CVD in individuals with type 2 diabetes [2].”
BackgroundGao, Y., Jiang, Y., Shi, R., Guo, Y., Xu, H., Min, C., Yang, Z., & Li, Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02033-w · Cited by 6
Self-citationTraditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?
Gladwell, L. R., Ahiarah, C., Rasheed, S., Rahman, S. M., & Choudhury, M. (2023) · Life · doi:10.3390/life14010023 · Cited by 7
“Epidemiological studies indicate that improvements in T2DM management have led to significant reductions in diabetes-associated cardiovascular morbidity [36].”
BackgroundJiang, Y., Yang, Z., Wang, J., Jiang, L., Han, P., Shi, R., & Li, Y. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1372519 · Cited by 5
Self-citationAlkali, N. H., Uloko, A. E., Chiroma, I. K., Mugana, A., Garba, M. A., Okpe, I. O., Gargah, E. T., Abdullahi, U. F., Shadrach, L., & Haladu, I. A. (2024) · Nigerian Postgraduate Medical Journal · doi:10.4103/npmj.npmj_54_24 · Cited by 5
Shi, S., Feng, Z., & Shen, J. (2025) · Public Health · doi:10.1016/j.puhe.2024.12.041 · Cited by 5
Amigó, N., Castelblanco, E., Julve, J., Martínez-Micaelo, N., Alonso, N., Hernández, M., Ribalta, J., Guardiola, M., Torán‐Monserrat, P., López-Lifante, V. M., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02636-5 · Cited by 5
Self-citationBacha, Z., Javed, J., Sheraz, M., Sikandar, M., Zakir, M., Ali, M. A., Khan, M., Iqbal, A., Rehman, A., Alam, U., et al. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001057 · Cited by 6
Pan, S., Dong, N., Yuan, H., Zhang, Y. X., He, H., Yin, T., Wang, Y., Gou, J., & Tang, X. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2564870 · Cited by 5
“GLP-1 receptor agonism modulates lipid homeostasis through enhanced lipid clearance, hepatic metabolism, and reverse cholesterol transport [37,38].”
Liu, X., Li, C., Huo, X., Liu, J., Liu, J., Cao, W., & Zheng, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-36923-2 · Cited by 5
“Frequent hyperglycemia induces vascular endothelial dysfunction through oxidative stress and inflammatory responses, which promotes the formation of atherosclerosis and increases the risk of CVD in T2DM patients 48,49 .”
Ding, X., Bai, G., Liu, X., Dong, Y., Chai, Y., Han, B., Meng, X., & Lei, H. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1744708 · Cited by 5
Wong, W. J., Nguyen, T. N., Fortin, M., & Harrison, C. M. (2024) · Australian Journal on Ageing · doi:10.1111/ajag.13282 · Cited by 5
Menzaghi, C., Marucci, A., Mastroianno, M., Ciaccia, G. D., Armillotta, M. P., Prehn, C. P., Salvemini, L., Mangiacotti, D., Adamski, J., Fontana, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae593 · Cited by 5
Krittayaphong, R., Treesuwan, W., Pramyothin, P., Songsangjinda, T., Kaolawanich, Y., Srivanichakorn, W., Jangtawee, P., Yindeengam, A., Tanapibunpon, P., & Vanavichit, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-72246-w · Cited by 7
Duan, X.-Y., Fu, J., Sun, L.-N., Mu, Z., & Xiu, S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i10.2081 · Cited by 5
Type 2 diabetes and colorectal cancer: genetic causality explored via Mendelian randomization
Ke, Q., Huang, Y., Cheng, L., Lin, C., Zhao, L., Huang, W., Chen, Z., Xu, Y., Huang, Y., Cai, L., et al. (2024) · Discover Oncology · doi:10.1007/s12672-024-01621-w · Cited by 5
The levels of adropin and its therapeutic potential in diabetes
Skrzypski, M., Wojciechowicz, T., Rak, A., Krążek, M., Fiedorowicz, J., Strowski, M. Z., & Nowak, K. W. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0117 · Cited by 7
Khalil, N. A., Abulfadl, Y. S., Bishr, M. M., Mostafa, N. M., & Elkhawas, Y. A. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00817-3 · Cited by 5
Peng, Z., Gao, L., Zhang, L., Yao, R., Li, X., Deng, L. J., Fan, J., Ying, L., & Wang, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146577 · Cited by 5
“Cardiovascular disease is the most common complication and accounts for at least 50% mortality in patients with T2D [2,3].”
Lee, W.-R., Han, K., Chang, Y. J., Park, S., & Kim, W. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04509-3 · Cited by 5
“Apart from cerebrovascular diseases, chronic hyperglycemia can also escalate the risk of developing vascular complications resulting in a loss of healthy life years due to cardiovascular diseases [35, 36].”
Syabariyah, S., Wardani, P. P. K., Aisyah, P. S., & Hisan, U. K. (2024) · Family Medicine & Primary Care Review · doi:10.5114/fmpcr.2024.134712 · Cited by 7
Guan, J., Abudouaini, H., Lin, K., & Yang, K. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01369-x · Cited by 6
“T2DM patients with RIR exhibit a substantially elevated risk of cardiovascular events, including myocardial infarction, stroke, and cardiovascular mortality [74], highlighting the urgent need for effective management strategies.”
BackgroundRetractedFedorov, S. V., Didushko, О. М., Nyshchuk-Oliinyk, N. B., Позур, Н. З., Bielinskyi, M. V., & Herashchenko, A. S. (2024) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.3.2024.1385 · Cited by 5
Shen, L., Shi, K., Yang, Z., Guo, Y., Shi, R., Jiang, Y., Yan, W., & Li, Y. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02372-2 · Cited by 5
“Type 2 diabetes mellitus (T2DM) and its related cardiovascular diseases have extensive effects on the health and economies of communities [1].”
BackgroundSelf-citationMobasher, M. A., Shabana, M. A., Germoush, M. O., Abuzinadah, N. Y., Abd-elhameed, A., Baioumy, S. A., Elkot, M., & Esawy, M. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-75543-6 · Cited by 5
Shabil, M., Bushi, G., Yadav, A., Ahmed, M., Kishore, J., Lekamwasam, S., & Joshi, A. (2023) · The Evidence · doi:10.61505/evidence.2023.1.1.3 · Cited by 5
Jiang, S., Gao, X., Diao, H., Zhang, Y., Lu, G., Liu, X., & Li, Y. (2026) · JMIR mHealth and uHealth · doi:10.2196/70429 · Cited by 6
“This highlights that, beyond glycemic control, managing cardiovascular risk factors is also essential in T2DM population [102].”
Self-citationCorrelation between the atherogenic index of plasma and risk of diabetic retinopathy
Zhang, Y., Chen, G., & Jing, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1565414 · Cited by 4
Liu, M., Liu, F., Diljhumal, A., Yang, J., Wang, Y., Ye, M., Jia, T., & Gao, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1629294 · Cited by 4
Magliano, D. J., Morton, J. I., Chen, L., Sacre, J. W., Salim, A., Gong, J. Y., Carstensen, B., Gregg, E. W., Arffman, M., Booth, G. L., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00398-5 · Cited by 4
Akintunde, A. A., Olamoyegun, M. A., Akinlade, M. O., Yusuf, O. A., & Salawu, A. A. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01337-8 · Cited by 4
“The close association between type 2 DM and CVD has led to the common soil hypothesis, postulating that both conditions share common genetic and environmental factors influencing this associa - tion [ 5 , 6].”
Zhang, Y., Jiong, O. X., Tang, S., Tang, Y. C., Wong, C. T., Ng, C. S., & Quan, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15474 · Cited by 4
Shen, L., Shi, R., Yang, Z., Gao, Y., Jiang, Y., Fang, H., Min, C., & Li, Y. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998277127231211063107 · Cited by 4
“This suggests that PS may gradually decrease with worsening eGFR and accumulation of uric acid [94].”
BackgroundSelf-citationShi, L., & Li, N. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i8.104180 · Cited by 4
Ayalew, T. L., Haile, K. E., Feleke, M. G., Zewudie, B. T., & Chichiabellu, T. Y. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03443-0 · Cited by 4
“Notably, cardiovascular (CV) events are a leading factor in the increased risk of early death in patients with type 2 diabetes mellitus (T2DM) and are a growing concern to human health globally [16, 17].”
BackgroundInfluentialOjeda‐Rodríguez, A., Alcala-Diaz, J. F., Rangel-Zúñiga, O. A., Larriva, A. P. A.-D., Gutierrez-Mariscal, F. M., Torres-Peña, J. D., Mora-Ortiz, M., Romero‐Cabrera, J. L., Luque, R. M., Ordovás, J. M., et al. (2024) · Antioxidants · doi:10.3390/antiox13010125 · Cited by 5
“This metabolic disease, characterized by insulin resistance and beta-cell malfunction, can result in severe micro-and macrovascular complications associated with an increased risk of cardiovascular disease [2].”
BackgroundGonzalez, J. M., Duarte, M., Gattamorta, K. A., Salamanca, M., Diaz, I. D. P., Marroquin, J. C. R., & Clochesy, J. M. (2025) · Discover Health Systems · doi:10.1007/s44250-025-00177-y · Cited by 4
“While diabetes had a lower prevalence of 10.04%, it remains a significant concern, especially given its long-term impact on cardiovascular health [28–30].”
InfluentialShahid, M. H., Ali, N., Ratnala, M., Ishaque, R., Raja, H. G., Rahbani, R., Ali, M. A., Mohiuddin, M., Idrees, H. B., Chowdhury, N. J., et al. (2025) · Cureus · doi:10.7759/cureus.83925 · Cited by 7
“Patients with T2DM are at a significantly elevated risk of experiencing major adverse cardiovascular events (MACE), including myocardial infarction, stroke, heart failure, and cardiovascular-related death [2,3].”
In silico study on antidiabetic and antioxidant activity of bioactive compounds in Ficus carica L
Raman, A. P. S., Pongpaiboon, S., Bhatia, R., Dabodhia, K. L., Kumar, A., Kumar, D., Jain, P., Sagar, M., Singh, P., & Kumari, K. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2240425 · Cited by 4
“Diabetes mellitus is simply metabolic disorders characterized by elevated blood sugar levels due to insufficient insulin secretion (Ma et al., 2022).”
Li, Y., Lin, L., Zhang, W., Wang, Y., & Guan, Y. (2024) · BMC Neurology · doi:10.1186/s12883-024-03969-6 · Cited by 3
Self-citationKunina, H., Franzén, S., & Kjellsson, M. C. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13301 · Cited by 3
Burgeiro, A., Santos, D., Fonseca, A. C. R. G., Baldeiras, I., Leal, E. C., Moura, J., Costa-Nunes, J., Seraphim, P. M., Pinho, A. C. O., Canotilho, A., et al. (2025) · Metabolites · doi:10.3390/metabo15070481 · Cited by 3
“In addition, almost two-thirds of patients with CVD have abnormal glucose homeostasis [2] and the prevalence of CAD in subjects with DM is about 12% [3].”
Aberle, J., Duerschmied, D., Grond, M., Lehrke, M., Martin, S., Tröbs, S., Schultze, M., Kossack, N., Richter, L. M., & Gabler, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02864-9 · Cited by 3
Zhang, Y., Ding, S., Li, W., Wang, X., Lv, J., Niu, Q., & Zhang, Q. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1653730 · Cited by 3
“It accounts for over 90% of global diabetes cases and exhibits a trend toward younger onset, and represents a major public health burden (1, 2).”
ROLE OF VITAMIN D IN CARDIOVASCULAR COMPLICATIONS OF METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE
Pivtorak, K. V., Ivanchuk, O., Pivtorak, N., Бурков, М. В., Pashinskyi, Y. M., & Shcherbeniuk, N. V. (2025) · World of Medicine and Biology · doi:10.26724/2079-8334-2025-3-93-235-241 · Cited by 3
García-Fernández, H., Arenas‐Montes, J., Gutierrez-Mariscal, F. M., Alcala-Diaz, J. F., Allais, A., Larriva, A. P. A.-D., Luque-Córdoba, D., Torres-Peña, J. D., Romero‐Cabrera, J. L., Luque, R. M., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1527406 · Cited by 3
Stougiannou, T. M., Koufakis, T., Παπάνας, Ν., & Karangelis, D. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47110911 · Cited by 3
Khattab, M. A., Khalil, S. H. A., Bassyouni, A., Fawzy, F., Elgayar, A. H., Elebrashy, I., Elhadidy, K. E., Abdallah, K., El-Hefnawy, M. H., Halawa, M. R., et al. (2025) · BMC Family Practice · doi:10.1186/s12875-025-03091-7 · Cited by 4
“Both DM and HF are considered major risk factors for each other [70, 91].”
InfluentialJahan, H., Fatima, U., Asad, S., Zahoor, S., Tufail, P., Zainab, D., Siddiqui, N. N., Ullah, A., Pizzi, M., & Choudhary, M. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.01.004 · Cited by 3
Physical Activity and Cardiovascular Health
Polyak, A., Lee, A., & Gulati, M. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/3341765 · Cited by 4
“CVD is a major complication of diabetes and is associated with increased risk of ischemic heart disease, heart failure, coronary artery disease, and peripheral artery disease [52].”
Lopes, A. C., Lourenço, O. M., Roque, F., & Morgado, M. (2023) · Biomedicines · doi:10.3390/biomedicines11020256 · Cited by 4
“There is a close link between T2DM and cardiovascular diseases, which are the most prevalent cause of morbidity and mortality in diabetic patients [54,55].”
BackgroundPokrovskaya, E. V., Shestakova, E. A., & Shestakova, M. V. (2023) · Diabetes Mellitus · doi:10.14341/dm13088 · Cited by 3
Sobha, S. P., Sankar, J., Muthusamy, K., & Ebenezar, K. K. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10823-4 · Cited by 3
“Furthermore, T2DM patients with CVD are more likely to experience the adverse outcomes and an increased risk of early death with oxidative stress playing a vital role (Ma et al. 2022).”
Sabarathinam, S. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-024-10044-y · Cited by 3
“However, the convoluted and multilateral nature of the linkage connecting Diabetes and CVD poses a diffi-culty in addressing T2DM and lowering CV episodes (Ma et al. 2022).”
O’Sullivan, J. L., Alonso-Pérez, E., Färber, F., Fuellen, G., Rudolf, H., Heisig, J. P., Kreyenfeld, M. R., & Gellert, P. R. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01533-3 · Cited by 4
Ning, W., Peng, X., Zhang, X., Basit, A., Ovatlarnporn, C., & Olatunji, O. J. (2025) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2025.101769 · Cited by 3
Pan, C., Wang, T., Yin, R., Tang, X., & Hu, C. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.99151 · Cited by 3
Shah, M. U., Roebuck, A., Srinivasan, B., Squires, P. E., Hills, C. E., Inghels, M., & Lee, K. (2025) · Diabetic Medicine · doi:10.1111/dme.70030 · Cited by 4
Seijas‐Amigo, J., Salgado‐Barreira, Á., Castelo-Dominguez, R., Pérez-Álvarez, M. T., Ponce-Piñón, B., Fernández-Silva, M., Rodríguez-Barreiro, M., Pereira-Pía, M., Iglesias-Moreno, J. M., Gago-García, M., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103312 · Cited by 3
Underweight and cardiovascular risk in Type 2 diabetes: a Korean nationwide study
Park, J., Han, K., Choe, H. J., Jang, H. N., Kwon, H. M., Park, S., Rhee, E., Moon, S. J., & Lee, W. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf903 · Cited by 4
Gomaa, S. H., Shehata, G. M., Ooda, S. A., & Eldeeb, M. K. (2022) · Journal of The Arab Society for Medical Research · doi:10.4103/jasmr.jasmr_18_22 · Cited by 3
Genomic risk prediction of cardiovascular diseases among type 2 diabetes patients in the UK Biobank
Ye, Y., Hu, J., Pang, F., Cui, C., & Zhao, H. (2024) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2023.1320748 · Cited by 3
Aydemir, D., Salman, N., Kerimzade, U., Aykaç, M., Ulutin, T., Kömürcü-Bayrak, E., Dağıstanlı, F. K., Alaca, B. E., & Ulusu, N. N. (2024) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2024.127497 · Cited by 3
Poonam, W., Kolhe, M. H., Mate, M. K., Bhor, R. J., Bhalerao, P. S., & Mhaske, M. P. (2024) · International Journal of Pharmaceutical Investigation · doi:10.5530/ijpi.14.4.123 · Cited by 3
Fan, X., Liu, Y., Chen, X., Xu, Y., Wu, W., Li, F., Liu, G., Chen, X., Zhang, C., & Zhou, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15947 · Cited by 3
Wu, G., He, W., Rao, H., Lin, L., He, X., & Hou, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1470523 · Cited by 3
“Hyperglycemia, insulin resistance, and associated metabolic disturbances characteristic of type 2 diabetes contribute to the development of atherosclerosis and endothelial dysfunction, leading to cardiovascular complications (15).”
Swarnakar, R., Sahu, D., Bahinipati, J., Pradhan, T., Meher, D., Sarangi, R., & Mahapatra, S. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1256_24 · Cited by 3
“[4] Furthermore, low‑density lipoproteins (LDL) are transformed into smaller, potentially more atherogenic lipoproteins known as small dense LDL.”
Kanumilli, N., Butler, J., Makrilakis, K., Rydén, L., Vallis, M., Wanner, C., Zieroth, S. R., Alhussein, A., & CHENG, A. Y. Y. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01418-0 · Cited by 3
A sensitivity indicator screening and intelligent classification method for the diagnosis of T2D-CHD
Li, J., & Ying, C. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1358066 · Cited by 2
Differences in splicing factors may predict type 2 diabetes remission in the CORDIOPREV study
Ojeda‐Rodríguez, A., Torres-Peña, J. D., Larriva, A. P. A.-D., Rangel-Zúñiga, O. A., Podadera-Herreros, A., Boughanem, H., G-García, M. E., López-Moreno, A., Katsiki, N., Luque, R. M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111527 · Cited by 2
Moharamzadeh, S., Kashef, M., Salehpour, M., Torabi, M., Vesali, S., Samsonchi, Z., & Hajizadeh‐Saffar, E. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01541-3 · Cited by 2
“Type 2 diabetes (T2D), a major public health problem [1], is a glucose metabolism disorder and one of the main causes of a variety of cardiovascular problems [2], specially pathological structural changes in cardio-myocytes [3].”
Nardi, E., Prastaro, M., Santoro, C., Gallo, L., Simeoli, L., Fontanarosa, S., Paolillo, S., Gargiulo, P., Esposito, G., & Filardi, P. P. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104033 · Cited by 3
The Impact of Metformin on BNP Levels: A Potential Cardioprotective Role in Type 2 Diabetes
Hoca, E., Kalaycı, N., Ahbab, S., Engin, İ., & Ataoğlu, H. E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082733 · Cited by 2
“Cardiovascular diseases (CVD) continue to be the most common cause of morbidity and mortality during the course of type 2 diabetes (T2D) [1].”
Lee, C.-W., & Myung, S. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.05.021 · Cited by 3
Addis, Z., Berhie, A. Y., Abate, T. W., Belay, B. M., Wale, H., Tega, A., & Alene, T. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-086054 · Cited by 2
Targeting the non-neuronal cholinergic machinery: A novel approach to mitigate cardiac aging
Chakraborty, S., Tiwari, V., & Banerjee, S. K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102782 · Cited by 2
Ghajar, M., Ghafourian, M. S., Tarkiani, S., Tork, A. N., Ramezani, A., Zolfaghari, B., & Palangi, M. G. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07690-5 · Cited by 2
Hu, L., Wang, Z., Feng, L., Jia, Y., Nie, Y., Khalifa, I., Zhang, H., Liang, X., & Liu, B. (2025) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.70058 · Cited by 2
“6 Although current clinical treatments, such as insulin injections and oral hypoglycemic agents (e.g. sulfonylureas and biguanides), 7 are effective in controlling blood glucose levels, their long-term use often leads to severe side effects and organ damage.”
Liu, C., Young, A., Abi, N., Chen, J., Gyorfy, M. F., Li, Y., Sun, S., Zhou, J. J., & Sun, Y. V. (2025) · Epigenomics · doi:10.1080/17501911.2025.2540273 · Cited by 4
“Mendelian randomization (MR) analyses suggested a causal relationship between DNA methylation and CHD, and provided strong evidence that blood DNAm patterns are prospectively associated with incident CHD [28].”
Self-citation
Metadata
- Authors
- Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B.
- Venue
- Cardiovascular Diabetology
- Published
- 2022-05-14
- Volume
- 21
- Issue
- 1
- Pages
- 74-74
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC9107726
- OpenAlex
- W4280586315
- Cited by
- 464
- References
- 137
- Citations by year
- 2026: 97 · 2025: 153 · 2024: 137 · 2023: 69 · 2022: 8
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- the Lanzhou Chengguan District Science and Technology Plan Project (2021-9-19)
- the hospital fund of the First Hospital of Lanzhou University (ldyyyn2020-93)
- the Construction Program of Gansu Provincial Clinical Medical Research Center for Endocrine Diseases (20JR10FA667)
- the Special Funds of Science and Technology Development of the Chinese Central Government to guide Local (1004TCYA032)
- the Gansu Provincial Natural Science Foundation (20JR10RA681)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular disease, personalized medicine, cardiovascular risk management, glycemic control, blood pressure control, lipid-lowering therapy, glucose-lowering agents, antiplatelet therapy, cardiovascular disease prevention, low- and middle-income countries
- MeSH terms
- Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Lipids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
